Limits...
Liposomal delivery systems for intestinal lymphatic drug transport

View Article: PubMed Central - PubMed

ABSTRACT

Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocyte-derived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.

No MeSH data available.


Types of lipidic prodrug: a fatty acids, b glycerides and c phospholipids
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5120490&req=5

Fig4: Types of lipidic prodrug: a fatty acids, b glycerides and c phospholipids

Mentions: Drugs modified with a lipid moiety, such as a fatty acid, glyceride, or phospholipid, show increased lipophilicity (Fig. 4). These lipid-conjugated drugs can be associated into enterocyte-derived chylomicrons. However, such modified drugs should be considered as novel entities because this modification could raise problems of safety and toxicity. In addition, confirmation should be obtained that lipid-conjugated drugs show efficacy identical or similar to that of the original drug [1, 12, 13].Fig. 4


Liposomal delivery systems for intestinal lymphatic drug transport
Types of lipidic prodrug: a fatty acids, b glycerides and c phospholipids
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5120490&req=5

Fig4: Types of lipidic prodrug: a fatty acids, b glycerides and c phospholipids
Mentions: Drugs modified with a lipid moiety, such as a fatty acid, glyceride, or phospholipid, show increased lipophilicity (Fig. 4). These lipid-conjugated drugs can be associated into enterocyte-derived chylomicrons. However, such modified drugs should be considered as novel entities because this modification could raise problems of safety and toxicity. In addition, confirmation should be obtained that lipid-conjugated drugs show efficacy identical or similar to that of the original drug [1, 12, 13].Fig. 4

View Article: PubMed Central - PubMed

ABSTRACT

Intestinal lymphatic drug delivery has been widely studied because drugs can bypass the first-pass metabolism in the liver via the lymphatic route, which increases oral bioavailability. Various lipid-based nanoparticles have been used to deliver hydrophobic drugs to the lymphatic pathway. This review focuses on the liposomal delivery systems used for intestinal lymphatic drug transport. Liposomal formulations have attracted particular attention because they can stimulate the production of chylomicrons and the incorporated drugs readily associate with enterocyte-derived chylomicrons, enhancing lymphatic drug transport. We believe that a full understanding of their contribution to intestinal drug translocation will lead to effective oral delivery with liposomal formulations.

No MeSH data available.